Search This Blog

Wednesday, June 15, 2016

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment (NYSE:LLY)

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.